Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Jul 02, 2024 2:27pm
98 Views
Post# 36114855

RE:RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:RE:How does Accelerated Approval work In a presentation late last year, a fireside chat I think, Matt stated that the Phase III for mBC would be a standard double blind study. Dr Heineken stated that the bracelet-1 trial was not designed for statisical significance..? kinda begs the question why run the effing thing then, but hey ho...

There will be NO Accelerated Approval... if it were a possibility, ONCY management would have signalled this long ago. Funny how no analysts ever asked that question either... seems its just Notable who would have everyone believe its a possibility... 

How long you been posting about billions of dollars for a buyout Notable... is it 3 years or 4 years now... and how has the stock performed in that time... IND-213, ONCY's go to Phase II mBC trial, started in 2012... there is something wrong in the state of Denmark folks...

So what will it take to get a partner on board... hmmm, final bracelet-1 data perhaps?.. and they won't declare the Phase III trial setup before that. Data is not coming until Q4.. so realistically there are NO inflection points for 3 months or so... 

Be prepared for the stock price to pretty much sit where it is for most of the year... that's why I'm practically out of this company. GLTA

Key patents expire in 2027, which means they cannot hope to get this approved before that happens... what a sad sh&% show this has been. No wonder Matty had a breakdown.

<< Previous
Bullboard Posts
Next >>